Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis

Authors

DOI:

https://doi.org/10.33084/bjop.v7i3.7218

Keywords:

Nintedanib, Idiopathic Pulmonary Fibrosis, COACH server-Binding site predictor, ADMET-SAR properties

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease due to aggregation of fibroblasts on lung parenchyma. Nintedanib, an indolinone-derived tyrosine kinase inhibitor (TKi) has been approved for the treatment of IPF and it is a well-known inhibitor of platelet-derived growth factor (PDGF) receptor-α and -β, fibroblast growth factor (FGF) receptor-1–3 and vascular endothelial growth factor (VEGF) receptor-1–3. This study aims to evaluate the binding interaction between new therapeutic protein candidates for IPF such as autotaxin, galectin-3, interleukin-13, chitotriosidase-1, JNK, RhoE-ROCK-1, ROCK-2 against nintedanib. In this investigation we predicted, computed, and analyzed the binding interactions of the drug nintedanib using an in silico approach called molecular docking. Our docking studies demonstrated that RhoE-ROCK1 and autotaxin showed strong binding affinities towards nintedanib compared to known targets such as VEGFR2 and FGFR1. We can therefore hypothesize a further contribution of nintedanib to the improvement of pathology due to its affinity towards new targets in the pathogenesis of IPF. The next step will be to evaluate the effects of this affinity in vitro on specific cellular models.

Views: 843Downloads: 530

Downloads

Download data is not yet available.

Author Biographies

References

Phan THG, Paliogiannis P, Nasrallah GK, Giordo R, Eid AH, Fois AG, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci. 2021;78(5):2031–57. DOI: 10.1007/s00018-020-03693-7; PMCID: PMC7669490; PMID: 33201251

Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1):32. DOI: 10.1186/s12931-018-0730-2; PMCID: PMC5824456; PMID: 29471816

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primer. 2017;3:17074. DOI: 10.1038/nrdp.2017.74; PMID: 29052582

Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345(7):517–25. DOI: 10.1056/nejmra003200; PMID: 11519507

Degryse AL, Lawson WE. Progress Toward Improving Animal Models for Idiopathic Pulmonary Fibrosis. Am J Med Sci. 2011;341(6):444–9. DOI: 10.1097/maj.0b013e31821aa000; PMCID: PMC3103078; PMID: 21613932

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(146):170057. DOI: 10.1183/16000617.0057-2017; PMCID: PMC9488585; PMID: 29212837

Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, et al. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019;58(9):1131–47. DOI: 10.1007/s40262-019-00766-0; PMCID: PMC6719436; PMID: 31016670

Kolb M, Bonella F, Wollin L. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med. 2017;131:49–57. DOI: 10.1016/j.rmed.2017.07.062; PMID: 28947042

Li R, Jia Y, Kong X, Nie Y, Deng Y, Liu Y. Novel drug delivery systems and disease models for pulmonary fibrosis. J Controlled Release. 2022;348:95–114. DOI: 10.1016/j.jconrel.2022.05.039; PMID: 35636615

Hilberg F, Tontsch-Grunt U, Baum A, Le AT, Doebele RC, Lieb S, et al. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther. 2018;364(3):494–503. DOI: 10.1124/jpet.117.244129; PMCID: PMC6040086; PMID: 29263244

Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, prodanovich PC, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010;160(7):1699–713. DOI: 10.1111/j.1476-5381.2010.00828.x; PMCID: PMC2936842; PMID: 20649573

Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45–54. DOI: 10.1038/nm1685; PMID: 18066075

Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic Acid signaling. Biomol Ther. 2015;23(1):1–11. DOI: 10.4062/biomolther.2014.109; PMCID: PMC4286743; PMID: 25593637

Cuozzo JW, Clark MA, Keefe AD, Kohlmann A, Mulvihill M, Ni H, et al. Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry. J Med Chem. 2020;63(14):7840–56. DOI: 10.1021/acs.jmedchem.0c00688; PMID: 32584034

Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(5):2002559. DOI: 10.1183/13993003.02559-2020; PMCID: PMC8156151; PMID: 33214209

Shimizu Y, Dobashi K, Sano T, Yamada M. Rock Activation in Lung of Idiopathic Pulmonary Fibrosis with Oxidative Stress. Int J Immunopathol Pharmacol. 2014;27(1):37–44. DOI: 10.1177/039463201402700106; PMID: 24674677

Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67(1):103–17. DOI: 10.1124/pr.114.009381; PMCID: PMC4279074; PMID: 25395505

Zhou Y, Huang X, Hecker L, Kurundkar D, Kurundkar A, Liu H, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123(3):1096–108. DOI: 10.1172/jci66700; PMCID: PMC3582144; PMID: 23434591

Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779–88. DOI: 10.1172/jci5909; PMCID: PMC408149; PMID: 10079098

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–96. DOI: 10.1056/nejmoa1804092; PMID: 29782217

Panettieri Jr RA, Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511–25. DOI: 10.1016/s2213-2600(18)30184-x; PMID: 29792288

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–96. DOI: 10.1016/s2213-2600(16)30265-x; PMID: 27616196

Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6(8):627–35. DOI: 10.1016/s2213-2600(18)30181-4; PMID: 29792287

Di Rosa M, Malaguarnera L. Chitotriosidase: A New Inflammatory Marker in Diabetic Complications. Pathobiology. 2016;83(4):211–9. DOI: 10.1159/000443932; PMID: 27116685

Koralewski R, Dymek B, Mazur M, Sklepkiewicz P, Olejniczak S, Czestkowski W, et al. Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. J Med Chem. 2020;63(24):15527–40. DOI: 10.1021/acs.jmedchem.0c01179; PMID: 33078933

Sklepkiewicz P, Dymek BA, Mlacki M, Koralewski R, Mazur M, Nejman-Gryz P, et al. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. Eur J Pharmacol. 2022;919:174792. DOI: 10.1016/j.ejphar.2022.174792; PMID: 35122869

Alcorn JF, van der Velden J, Brown AL, McElhinney B, Irvin CG, Janssen-Heininger YMWJ. c-Jun N-Terminal Kinase 1 Is Required for the Development of Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2009;40(4):422–32. DOI: 10.1165/rcmb.2008-0174oc; PMCID: PMC2660560; PMID: 18836136

Bennett BL. c-Jun N-terminal kinase-dependent mechanisms in respiratory disease. Eur Respir J. 2006;28(3):651–61. DOI: 10.1183/09031936.06.00012106; PMID: 16946096

Lee VY, Schroedl C, Brunelle JK, Buccellato LJ, Akinci OI, Kaneto H, et al. Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway. Am J Physiol Lung Cell Mol Physiol. 2005;289(4):L521–8. DOI: 10.1152/ajplung.00340.2004; PMID: 16148050

Lin CH, Yu MC, Tung WH, Chen TT, et al. Connective tissue growth factor induces collagen I expression in human lung fibroblasts through the Rac1/MLK3/JNK/AP-1 pathway. Biochim Biophys Acta. 2013;1833(12):2823–33. DOI: 10.1016/j.bbamcr.2013.07.016; PMID: 23906792

Baroroh U, Muscifa ZS, Destiarani W, Rohmatullah FG, Yusuf M. Molecular interaction analysis and visualization of protein-ligand docking using Biovia Discovery Studio Visualizer. Indones J Comput Biol. 2023;2(1):22-30. DOI: 10.24198/ijcb.v2i1.46322

Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023;13(1):13398. DOI: 10.1038/s41598-023-40160-2; PMCID: PMC10435576; PMID: 37592012

Yang J, Roy A, Zhang Y. Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics. 2013;29(20):2588-95. DOI: 10.1093/bioinformatics/btt447; PMCID: PMC3789548; PMID: 23975762

Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Compout Aided Drug Des. 2011;7(2):146-57. DOI: 10.2174/157340911795677602; PMCID: PMC3151162; PMID: 21534921

Fu Y, Zhao J, Chen Z. Insights into the Molecular Mechanisms of Protein-Ligand Interactions by Molecular Docking and Molecular Dynamics Simulation: A Case of Oligopeptide Binding Protein. Comput Math Methods Med. 2018;2018:3502514. DOI: 10.1155/2018/3502514; PMCID: PMC6305025; PMID: 30627209

Zhang W, Bell EW, Yin M, Zhang Y. EDock: blind protein-ligand docking by replica-exchange monte carlo simulation. J Cheminform. 2020;12(1):37. DOI: 10.1186/s13321-020-00440-9; PMCID: PMC7251717; PMID: 33430966

Downloads

Published

08/30/2024

Issue

Section

Analytical Pharmacy-Medicinal Chemistry

Categories

How to Cite

1.
Balasubramanian HB, Biswas S, Talmon M, Patrucco F, Balbo PE, Fresu LG, et al. Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis. Borneo J Pharm [Internet]. 2024 Aug. 30 [cited 2026 Nov. 19];7(3):264-77. Available from: https://journal.umpr.ac.id/index.php/bjop/article/view/7218

Similar Articles

91-100 of 193

You may also start an advanced similarity search for this article.